Tag: Covaxin

The World Health Organisation (WHO) granted Emergency Use Listing approval to India's indigenously-developed Covid vaccine, Bharat Biotech's Covaxin on Wednesday.

India's drug regulator, the Central Drugs Standards Control Organisation (CDSCO) has approved the extension of shelf life of indigenously-developed Covid-19 vaccine Covaxin from nine to 12 months.

Five more countries on Monday recognised India's vaccine certificate, after Australia recognised Bharat Biotech's Covaxin for allowing entry of travellers who had received the vaccine

This recognition is for travellers aged 12 and over who have been vaccinated with Covaxin, and those 18 to 60 who have been vaccinated with BBIBP-CorV.

Hyderabad based Bharat Biotech is expected to submit the data by this weekend.

The Hyderabad-based Bharat Biotech had applied to the WHO on April 19 for Covaxin's Emergency Use Listing

The top court told the petitioner's counsel that it finds no error with the high court decision in the matter, and it will not entertain the petition.

Bharat Biotech recently said it has submitted all data pertaining to Covaxin to the WHO for the EUL and is awaiting feedback from the global health watchdog.

The Drugs and Comptroller General of India (DCGI) has given a go-ahead to Bharat Biotech's Covaxin for vaccination of children in the 2-18 years age group.

The Subject Expert Committee (SEC) has given the necessary approval for the administration of the anti-Covid vaccine to children.

There is no difference in antibodies produced by Covaxin and Covishield vaccines against the Covid-19 virus. This information was shared by Odisha Health Services Director Bijay Mohapatra on Monday (Sept 27).

Covaxin may soon receive Emergency Use Listing by the World Health Organisation (WHO), eventually enabling its recipients to travel abroad without mandatory quarantine, NITI Aayog's Member, Health, V.K. Paul said on Wednesday.

India's vaccination coverage against coronavirus under the mass vaccination drive has crossed the landmark of 63 crore. Over 73 lakh doses have been administered in the last 24 hours.

The antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection were compared with those individuals without prior evidence of infection.

The results of Phase II and III trials of COVAXIN are going on for children in the age group of 2-18 years. So, by September or just after it, we may have COVID-19 vaccines for children, said Priya Abraham, Director of ICMR-NIV